Literature DB >> 28724795

ALX receptor ligands define a biochemical endotype for severe asthma.

Isabell Ricklefs1, Ioanna Barkas1, Melody G Duvall1,2, Manuela Cernadas1, Nicole L Grossman1, Elliot Israel1, Eugene R Bleecker3, Mario Castro4, Serpil C Erzurum5, John V Fahy6, Benjamin M Gaston7, Loren C Denlinger8, David T Mauger9, Sally E Wenzel10, Suzy A Comhair5, Andrea M Coverstone11, Merritt L Fajt10, Annette T Hastie3, Mats W Johansson12, Michael C Peters6, Brenda R Phillips9, Bruce D Levy1.   

Abstract

BACKGROUND: In health, inflammation resolution is an active process governed by specialized proresolving mediators and receptors. ALX/FPR2 receptors (ALX) are targeted by both proresolving and proinflammatory ligands for opposing signaling events, suggesting pivotal roles for ALX in the fate of inflammatory responses. Here, we determined if ALX expression and ligands were linked to severe asthma (SA).
METHODS: ALX expression and levels of proresolving ligands (lipoxin A4 [LXA4], 15-epi-LXA4, and annexin A1 [ANXA1]), and a proinflammatory ligand (serum amyloid A [SAA]) were measured in bronchoscopy samples collected in Severe Asthma Research Program-3 (SA [n = 69], non-SA [NSA, n = 51] or healthy donors [HDs, n = 47]).
RESULTS: Bronchoalveolar lavage (BAL) fluid LXA4 and 15-epi-LXA4 were decreased and SAA was increased in SA relative to NSA. BAL macrophage ALX expression was increased in SA. Subjects with LXA4loSAAhi levels had increased BAL neutrophils, more asthma symptoms, lower lung function, increased relative risk for asthma exacerbation, sinusitis, and gastroesophageal reflux disease, and were assigned more frequently to SA clinical clusters. SAA and aliquots of LXA4loSAAhi BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA4.
CONCLUSIONS: Together, these findings have established an association between select ALX receptor ligands and asthma severity that define a potentially new biochemical endotype for asthma and support a pivotal functional role for ALX signaling in the fate of lung inflammation. TRIAL REGISTRATION: Severe Asthma Research Program-3 (SARP-3; ClinicalTrials.gov NCT01606826)FUNDING Sources. National Heart, Lung and Blood Institute, the NIH, and the German Society of Pediatric Pneumology.

Entities:  

Keywords:  Inflammation; Pulmonology

Year:  2017        PMID: 28724795      PMCID: PMC5518567          DOI: 10.1172/jci.insight.93534

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  47 in total

1.  Diminished lipoxin biosynthesis in severe asthma.

Authors:  Bruce D Levy; Caroline Bonnans; Eric S Silverman; Lyle J Palmer; Gautham Marigowda; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

Review 2.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

3.  FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.

Authors:  Paola Maderna; David C Cottell; Tiina Toivonen; Neil Dufton; Jesmond Dalli; Mauro Perretti; Catherine Godson
Journal:  FASEB J       Date:  2010-06-22       Impact factor: 5.191

4.  Acute phase reactants in allergic airway disease.

Authors:  Suna Büyüköztürk; Asli Akkor Gelincik; Sema Genç; Hikmet Koçak; Yildiz Oneriyidogan; Sacide Erden; Murat Dal; Bahattin Colakoglu
Journal:  Tohoku J Exp Med       Date:  2004-11       Impact factor: 1.848

5.  Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells.

Authors:  Amiram Ariel; Nan Chiang; Makoto Arita; Nicos A Petasis; Charles N Serhan
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

6.  Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation.

Authors:  Oliver Haworth; Manuela Cernadas; Rong Yang; Charles N Serhan; Bruce D Levy
Journal:  Nat Immunol       Date:  2008-06-22       Impact factor: 25.606

Review 7.  Future Research Directions in Asthma. An NHLBI Working Group Report.

Authors:  Bruce D Levy; Patricia J Noel; Michelle M Freemer; Michelle M Cloutier; Steve N Georas; Nizar N Jarjour; Carole Ober; Prescott G Woodruff; Kathleen C Barnes; Bruce G Bender; Carlos A Camargo; Geoff L Chupp; Loren C Denlinger; John V Fahy; Anne M Fitzpatrick; Anne Fuhlbrigge; Ben M Gaston; Tina V Hartert; Jay K Kolls; Susan V Lynch; Wendy C Moore; Wayne J Morgan; Kari C Nadeau; Dennis R Ownby; Julian Solway; Stanley J Szefler; Sally E Wenzel; Rosalind J Wright; Robert A Smith; Serpil C Erzurum
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

8.  Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma.

Authors:  Emiko Ono; Stefanie Dutile; Shamsah Kazani; Michael E Wechsler; Jun Yang; Bruce D Hammock; David Nobuhiro Douda; Yacine Tabet; Rayan Khaddaj-Mallat; Marco Sirois; Chantal Sirois; Edmond Rizcallah; Eric Rousseau; Richard Martin; E Rand Sutherland; Mario Castro; Nizar N Jarjour; Elliot Israel; Bruce D Levy
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

9.  Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling.

Authors:  Stefania Bena; Vincenzo Brancaleone; Ji Ming Wang; Mauro Perretti; Roderick J Flower
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

10.  Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation.

Authors:  N Chiang; I M Fierro; K Gronert; C N Serhan
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  12 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

3.  Club Cell Secretory Protein Deficiency Leads to Altered Lung Function.

Authors:  Jing Zhai; Michael Insel; Kenneth J Addison; Debra A Stern; William Pederson; Alane Dy; Joselyn Rojas-Quintero; Caroline A Owen; Duane L Sherrill; Wayne Morgan; Anne L Wright; Marilyn Halonen; Fernando D Martinez; Monica Kraft; Stefano Guerra; Julie G Ledford
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

4.  Treatment options in type-2 low asthma.

Authors:  Timothy S C Hinks; Stewart J Levine; Guy G Brusselle
Journal:  Eur Respir J       Date:  2021-01-21       Impact factor: 16.671

5.  Therapeutic efficacy of IL-17A neutralization with corticosteroid treatment in a model of antigen-driven mixed-granulocytic asthma.

Authors:  Katherine E Menson; Madeleine M Mank; Leah F Reed; Camille J Walton; Katherine E Van Der Vliet; Jennifer L Ather; David G Chapman; Bradford J Smith; Mercedes Rincon; Matthew E Poynter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

6.  Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma.

Authors:  Loren C Denlinger; Brenda R Phillips; Ronald L Sorkness; Eugene R Bleecker; Mario Castro; Mark D DeBoer; Anne M Fitzpatrick; Annette T Hastie; Jonathan M Gaffin; Wendy C Moore; Michael C Peters; Stephen P Peters; Wanda Phipatanakul; Juan Carlos Cardet; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin Gaston; Bruce D Levy; Deborah A Meyers; Kristie Ross; W Gerald Teague; Sally E Wenzel; Prescott G Woodruff; Joe Zein; Nizar N Jarjour; David T Mauger; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

7.  Pruning of the Pulmonary Vasculature in Asthma. The Severe Asthma Research Program (SARP) Cohort.

Authors:  Samuel Y Ash; Farbod N Rahaghi; Carolyn E Come; James C Ross; Alysha G Colon; Juan Carlos Cardet-Guisasola; Eleanor M Dunican; Eugene R Bleecker; Mario Castro; John V Fahy; Sean B Fain; Benjamin M Gaston; Eric A Hoffman; Nizar N Jarjour; David T Mauger; Sally E Wenzel; Bruce D Levy; Raul San Jose Estepar; Elliot Israel; George R Washko
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 30.528

8.  Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity.

Authors:  Ursula Smole; Naina Gour; Jordan Phelan; Gerhard Hofer; Cordula Köhler; Bernhard Kratzer; Peter A Tauber; Xiao Xiao; Nu Yao; Jan Dvorak; Luis Caraballo; Leonardo Puerta; Sandra Rosskopf; Jamila Chakir; Ernst Malle; Andrew P Lane; Winfried F Pickl; Stephane Lajoie; Marsha Wills-Karp
Journal:  Nat Immunol       Date:  2020-06-22       Impact factor: 31.250

Review 9.  Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease.

Authors:  Cindy Barnig; Tjitske Bezema; Philip C Calder; Anne Charloux; Nelly Frossard; Johan Garssen; Oliver Haworth; Ksenia Dilevskaya; Francesca Levi-Schaffer; Evelyne Lonsdorfer; Marca Wauben; Aletta D Kraneveld; Anje A Te Velde
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

10.  Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.

Authors:  Tuuli Lappalainen; Stephanie A Christenson; Silva Kasela; Victor E Ortega; Molly Martorella; Suresh Garudadri; Jenna Nguyen; Elizabeth Ampleford; Anu Pasanen; Srilaxmi Nerella; Kristina L Buschur; Igor Z Barjaktarevic; R Graham Barr; Eugene R Bleecker; Russell P Bowler; Alejandro P Comellas; Christopher B Cooper; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; Charles Langelier; Prescott G Woodruff
Journal:  Genome Med       Date:  2021-04-21       Impact factor: 15.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.